Multimodal chemoradiotherapy including interstitial brachytherapy enhances outcomes in FIGO stage IVA cervical cancer: a focus on tumor control and quality of life.

Median overall survival was notably longer in the brachytherapy group (108.0 months) compared to the non-brachytherapy group (51.7 months; 95% CI: 16.2–126.8), although this difference did not reach statistical significance (log-rank test: p = 0.6).

also in 111,027 other papers

Although patient age did not reach statistical significance ( p = 0.3), a clear trend toward improved outcomes in younger patients (< 50 years) was observed, consistent with prior studies [ 20 , 21 ].

also in 19,460 other papers